Home > Boards > US OTC > Medical - Drugs > Roche Holding Ltd. (RHHBY)

Roche Reports Positive Results In Breast Cancer Study

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
SAE Member Profile
 
Followed By 2
Posts 564
Boards Moderated 0
Alias Born 08/06/09
160x600 placeholder
FDA panel votes to keep indications for Merck, Roche bladder cancer drugs Seeking Alpha - 4/30/2021 7:58:15 AM
FDA panel votes to maintain breast cancer indication for Roche's Tecentriq Seeking Alpha - 4/27/2021 5:26:34 PM
Roche Gets FDA Approval for Cancer-Treatment Test Dow Jones News - 4/23/2021 6:47:00 AM
Roche Q1 sales beats forecast, 2021 outlook confirmed Seeking Alpha - 4/21/2021 5:35:48 AM
Roche Holding beats on revenue; 2021 outlook confirmed Seeking Alpha - 4/21/2021 4:43:18 AM
Roche Backs 2021 Views After 1Q Sales Fall Slightly Dow Jones News - 4/21/2021 1:54:00 AM
Novartis to help produce Roche's Actemra Seeking Alpha - 4/15/2021 5:38:12 AM
Roche’s Evrysdi continues to improve motor function, survival in babies with spinal muscular atrophy Seeking Alpha - 4/15/2021 3:11:36 AM
Novartis Enters Agreement With Roche on Production of the Latter's Drug Dow Jones News - 4/15/2021 2:14:00 AM
Roche's Spark in Gene-Therapy Collaboration With Senti Bio Dow Jones News - 4/13/2021 10:10:00 AM
Roche unit Spark Therapeutics inks deal to bolster gene therapy research platform Seeking Alpha - 4/13/2021 9:16:17 AM
Novartis, Genentech Get FDA OK of Self-Administered Xolair Dow Jones News - 4/12/2021 2:12:00 PM
Roche's Phase 3 Trial of Casirivimab, Imdevimab Shows Cut Risk of Symptomatic Covid-19 Infections Dow Jones News - 4/12/2021 1:52:00 AM
Roche's Elecsys COVID-19 antibody test now available in Canada Seeking Alpha - 4/6/2021 8:41:03 AM
PTC Therapeutics earns $20M milestone under Evrysdi deal with Roche Seeking Alpha - 4/1/2021 8:34:57 AM
Roche, PTC Therapeutics Gets European OK of Evrysdi in Spinal Muscular Atrophy Dow Jones News - 3/30/2021 6:56:00 AM
iTeos Therapeutics shares rise 4% as Wedbush ups price target Seeking Alpha - 3/25/2021 4:19:31 PM
Ixico Shares Fall as Roche Halts Huntington's Disease Trial Dow Jones News - 3/23/2021 11:59:00 AM
Ionis Pharmaceuticals Partner Stops Dosing in Huntington's Disease Study Dow Jones News - 3/23/2021 7:15:00 AM
Roche Covid-19 Antibody Trial Meets Primary Endpoint Dow Jones News - 3/23/2021 2:50:00 AM
Genentech: Dosing to Stop in Phase III Clinical Study of Tominersen Dow Jones News - 3/22/2021 4:58:00 PM
Ionis announces discontinuation of Huntington's disease studies Seeking Alpha - 3/22/2021 4:39:33 PM
Genentech's Tecentriq meets late-stage lung cancer study main goal Seeking Alpha - 3/22/2021 6:29:16 AM
Roche's Tecentriq Meets Primary Endpoint in Phase 3 Lung Cancer Study Dow Jones News - 3/22/2021 2:45:00 AM
Artelo Biosciences Shares Rise 8% on Acceptance Into U.K Oncology Program Dow Jones News - 3/19/2021 10:49:00 AM
SAE   Thursday, 12/08/11 11:16:26 AM
Re: None
Post # of 252 
Roche Reports Positive Results In Breast Cancer Study

Roche Holding AG (ROG.VX) Thursday said the results of its pivotal Phase III study with pertuzumab in HER2-positive metastatic breast cancer were positive, with a 6.1 month improvement in median progression free survival, from 12.4 months to 18.5 months.

MAIN FACTS:

- Roche today announced results from CLEOPATRA, the first randomised Phase III study of the investigational HER2-targeted medicine pertuzumab.

- The study compared the combination of pertuzumab, Herceptin (trastuzumab) and docetaxel chemotherapy to Herceptin and docetaxel alone in people with previously untreated HER2-positive metastatic breast cancer (mBC).

- People who received pertuzumab in combination with Herceptin and chemotherapy experienced a 38 percent reduction in the risk of their disease worsening or death (progression-free survival, or PFS), (HR=0.62; p-value=<0.0001).

- The median PFS improved by 6.1 months from 12.4 months for Herceptin and chemotherapy to 18.5 months for pertuzumab, Herceptin and chemotherapy.

- Overall survival (OS) data are currently immature, with a trend in favour of the pertuzumab combination.

- No new safety signals were observed and adverse events were consistent with those seen in previous studies of pertuzumab and Herceptin, either in combination or alone.

- The results will be presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium December 6-10 (Abstract # S5-5), and were featured in the official press program.

- Data were published yesterday in the online edition of the New England Journal of Medicine.

- Roche has submitted a Biologics License Application for pertuzumab to the U.S. Food and Drug Administration for people with previously untreated, HER2-positive metastatic breast cancer and a Marketing Authorization Application to the European Medicines Agency in the same indication.

-Zurich Bureau, Dow Jones Newswires, +41 43 443 80 47; zurichdjnews@dowjones.com

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences